The jury not only judged the lay-out of the presentation, but moreover the content and the impact of the study: ‘An outstanding contribution!’ Si Wang: ‘I didn’t expect to win at all. It was a big surprise for me. The results of this study are very promising and very clear. We showed that the PamGene technology could be a replacement of the uterotrophic assay. To be honest, there were four other winners, and there was no ranking.’
Si Wang works for the division of toxicology of the Wageningen Univsersity and Research Centre. He especially praises the collaboration with Pamgene: ‘Rene Houtman and Rinie van Beuningen contributed a lot to this study.’
The researchers tested a panel of 23 compounds with known estrogen activity. These compounds were correctly classified with the MARCoNI technology. Potencies determined by the PamGene in vitro assay correlate very well with the measurements by the standard in vivo uterotrophic assay. The conclusion of the study: the PamGene microarray is useful within a panel of in vitro test systems for estrogenicity testing, allowing easy high-throughput screening thereby contributing to reduce and ultimately replace current animal testing for (anti)estrogenic effects.
The study has quite a spin-off. ALTEX, the journal for alternatives for animal testing, accepted the manuscript on this study for publication.